Thalidomide In The Treatment Of Myelodysplastic Syndromes Application

Objective:from the "old drug new use" point of view,studies of thalidomide In myelodysplastic syndrome(MDS) the role of treatment.Methods:According to FAB classification select 47 cases of MDS patients as research subjects,divided into control group(A group) and treatment group(B group),A Group:Application Kangli long and all-trans retinoic acid oral,at the same time support the application of symptomatic treatment.B group:on the basis of the application of United thalidomide daily dose 200mg,Dayton bedtime clothing.Both require continuous medication for at least 6 months,respectively,with thalidomide before treatment,after 3 months and 6 months of further inspections in accordance with national standards to assess efficacy MDS clinical efficacy.Results:A group of five cases of remission,remission rate of 21.7.%,5 cases make progress,with a total effective rate was 43.5%.B group,13 cases of remission,6 cases of progress,the remission rate of 54.2%total effective rate was 79.2%.Remission rate compared to the two groups were significantly different(x~2=5.44,P＜0.025),there is the efficiency of the two groups compared were significantly different(x~2=15.7,P＜0.005).A group has 10 cases of treatment(basic remission+partial remission+ progress),the Hb before treatment increased more than 30g/L the average time for the 124.8±22.6 days.19 cases of group B patients with Hb increase effective 30g/more than the average time for 92.7±32.4 days,difference between two groups was significant(t=7. 51,P＜0.01).Transfusion of red blood cells were observed volume,A group has20 cases of transfusion records,the average infusion volume of 18.1±8.0u.Group B has 18 cases of transfusion records,an average of 10.6±7.0 u,upon inspection,the two groups have very significant difference(t=6.71,P＜0.001).Conclusion:Thalidomide(oral administration,serving Dayton bedtime 200mg/d) United Kangli long,retinoic acid treatment of myelodysplastic syndrome improve the remission rate and overall efficiency, the application of smaller doses of the low incidence of adverse reactions and well tolerated.